{"disease":{"id":"gvhd","name":"gvhd"},"drugs":{"marketed":[{"drug_id":"axatilimab","indication_name":"chronic graft-versus-host disease (cGVHD)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Niktimvo","generic_name":"AXATILIMAB","company_name":"Incyte Corp","drug_phase":"marketed","molecular_target":"","drug_class":"Colony Stimulating Factor-1 Receptor Blocker [EPC]","quality_score":10,"revenue":null,"mechanism":"Niktimvo blocks the Colony Stimulating Factor-1 Receptor to reduce inflammation and prevent damage to healthy tissues."},{"drug_id":"belumosudil","indication_name":"Chronic graft-versus-host disease (chronic GVHD)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rezurock","generic_name":"BELUMOSUDIL","company_name":"Kadmon Pharms Llc","drug_phase":"marketed","molecular_target":"Rho-associated protein kinase 1","drug_class":"","quality_score":55,"revenue":null,"mechanism":"Rezurock works by inhibiting the Rho-associated protein kinase 1 enzyme, which plays a key role in inflammation and immune response."}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT00128973","title":"Evaluation of Patients With Immune Function Abnormalities","phase":"","overall_status":"RECRUITING","enrollment_count":3500,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT05919511","title":"Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease","phase":"","overall_status":"RECRUITING","enrollment_count":1500,"lead_sponsor_name":"Incyte Corporation","has_results":false},{"nct_id":"NCT06615050","title":"A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":572,"lead_sponsor_name":"Incyte Corporation","has_results":false},{"nct_id":"NCT04284904","title":"Role of aGVHD Biomarkers on aGVHD Risks","phase":"","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"Chinese PLA General Hospital","has_results":false},{"nct_id":"NCT03139604","title":"GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":439,"lead_sponsor_name":"Incyte Corporation","has_results":true},{"nct_id":"NCT03112603","title":"A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":330,"lead_sponsor_name":"Incyte Corporation","has_results":true},{"nct_id":"NCT06083129","title":"Phase III Study Comparing GVHD Prophylaxis With ATG-thymoglobulin to ATLG-grafalon in Elderly Patients With Acute Myeloid Leukemia or Myelodysplasic Syndrome and Receiving an Allogeneic Hematopoietic Stem Cell Transplantation With a 10/10 HLA Matched Unrelated Donor","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":324,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT05052385","title":"ECP Combination Study","phase":"","overall_status":"COMPLETED","enrollment_count":319,"lead_sponsor_name":"European Society for Blood and Marrow Transplantation","has_results":false},{"nct_id":"NCT01295710","title":"Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":260,"lead_sponsor_name":"Neovii Biotech","has_results":true},{"nct_id":"NCT04061876","title":"First Line Therapy for High Risk Acute GVHD","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":198,"lead_sponsor_name":"Chinese PLA General Hospital","has_results":false},{"nct_id":"NCT05531266","title":"Umbilical Cord Mesenchymal Stem Cells as First-line Treatment for Patients With Acute Graft Versus Host Disease","phase":"NA","overall_status":"UNKNOWN","enrollment_count":182,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT07340723","title":"Novel First-line Therapies for Grade II Acute GVHD(Graft-versus-host Disease )","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":168,"lead_sponsor_name":"Daihong Liu","has_results":false},{"nct_id":"NCT05263999","title":"A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR)","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":158,"lead_sponsor_name":"Equillium","has_results":false},{"nct_id":"NCT03894488","title":"Clinical Evaluation of the Application of the FilmArray GI Panel in Post-HSCT Diarrhea Patients","phase":"","overall_status":"UNKNOWN","enrollment_count":150,"lead_sponsor_name":"Shanghai Children's Medical Center","has_results":false},{"nct_id":"NCT04946721","title":"2177GCCC:ID'Ing tx Targets and Biomarkers for Ocular Surface Disease in Pt w/ oGVHD","phase":"","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"University of Maryland, Baltimore","has_results":false},{"nct_id":"NCT06000982","title":"Comparison of Different Dose of Post-transplantation Cyclophosphamide as Graft Versus Host Disease Prophylaxis","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":138,"lead_sponsor_name":"Shanghai Jiao Tong University School of Medicine","has_results":false},{"nct_id":"NCT04167514","title":"Treatment of GVHD in Hematopoietic Stem Cell Transplant (HSCT) Recipients Using AAT Plus Corticosteroids (CS) Compared With Corticosteroids Alone","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":136,"lead_sponsor_name":"CSL Behring","has_results":true},{"nct_id":"NCT04373057","title":"Prebiotic Galacto-oligosaccharide and Acute GVHD","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":128,"lead_sponsor_name":"Duke University","has_results":false},{"nct_id":"NCT03631563","title":"ATG-F VS ATG for the Prevention of GVHD","phase":"PHASE2, PHASE3","overall_status":"UNKNOWN","enrollment_count":120,"lead_sponsor_name":"Fujian Medical University","has_results":false},{"nct_id":"NCT06364319","title":"Efficacy and Safety of Anti-CD25 rhMAb in the Treatment of Steroid-Refractory cGVHD","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":118,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT03042676","title":"Electronic Database for the Follow up of the ATG_FamilyStudy","phase":"","overall_status":"COMPLETED","enrollment_count":104,"lead_sponsor_name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","has_results":false},{"nct_id":"NCT05718791","title":"CXCL9 and EASIX for Prediction of Acute Graft Versus Host Disease","phase":"","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Henry Ford Health System","has_results":false},{"nct_id":"NCT04945096","title":"Outcomes of Patients After Allo-HSCT With Decitabine and NAC","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"The First Affiliated Hospital of Soochow University","has_results":false},{"nct_id":"NCT06864598","title":"The Application of Novel Identified CD8 Regulatory Precursors in Inducing Immune Tolerance After Allo-HSCT","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":100,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT07271498","title":"The Oral cGVHD as a Predictive Factor of Graft Versus Leukaemia Effect in Patients Who Received an Allograft","phase":"","overall_status":"COMPLETED","enrollment_count":93,"lead_sponsor_name":"Centre Hospitalier Universitaire de Nice","has_results":false},{"nct_id":"NCT06756061","title":"Comparing the Therapeutic Effects of Using Ruxolitinib and Steroids Concurrently to Steroids Alone as Initial Treatment In Patients Diagnosed With Chronic Graft-versus-host Disease at a Grade of Moderate or Higher Severity","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":88,"lead_sponsor_name":"Byung-Sik Cho","has_results":false},{"nct_id":"NCT04522843","title":"Analysis of Intestinal Defensin Expression in Acute GVHD","phase":"","overall_status":"COMPLETED","enrollment_count":80,"lead_sponsor_name":"University of Freiburg","has_results":false},{"nct_id":"NCT05790135","title":"Multiparametric Ultrasound Study in Diagnosing GvHD","phase":"NA","overall_status":"SUSPENDED","enrollment_count":75,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT06626737","title":"Dapagliflozin in Allo-HCT for aGVHD","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":72,"lead_sponsor_name":"The First Affiliated Hospital of Soochow University","has_results":false},{"nct_id":"NCT02953678","title":"A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":71,"lead_sponsor_name":"Incyte Corporation","has_results":true},{"nct_id":"NCT03846479","title":"Itacitinib for Low Risk GVHD","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":70,"lead_sponsor_name":"John Levine","has_results":true},{"nct_id":"NCT05544448","title":"In Vitro Effect Study of Interleukin-2 Muteins on Regulatory T Cells of Patients With Different Autoimmune, Allo-immune or Inflammatory Diseases","phase":"NA","overall_status":"COMPLETED","enrollment_count":67,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT06186804","title":"A Phase II Study Evaluating the Efficacy and Safety of ABSK021 (Pimicotinib)) in the Treatment of cGvHD Chronic Graft Versus Host Disease (cGvHD)","phase":"PHASE2","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":64,"lead_sponsor_name":"Abbisko Therapeutics Co, Ltd","has_results":false},{"nct_id":"NCT05873907","title":"A Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of AMG 592 in Healthy Participants","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":64,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT06075225","title":"MAP-guided Preemptive Therapy of aGvHD by Ruxolitinib","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":62,"lead_sponsor_name":"Sichuan University","has_results":false},{"nct_id":"NCT06590285","title":"Diagnostic Refinement and Educational Approaches in Managing Bone Marrow Transplantation","phase":"NA","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Scripps Health","has_results":false},{"nct_id":"NCT05214066","title":"Efficacy and Safety Study of 4-Day ATG Regimen for Prophylaxis of aGVHD in Matched Sibling Donor PBSCT","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":60,"lead_sponsor_name":"Chinese PLA General Hospital","has_results":false},{"nct_id":"NCT03064984","title":"Blood Based Eyedrops From Different Sources in the Treatment of Severe Keratopathy","phase":"NA","overall_status":"UNKNOWN","enrollment_count":60,"lead_sponsor_name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","has_results":false},{"nct_id":"NCT06469411","title":"Effect of PMSCs and Their Secretome for the Treatment of GvHD","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Tabriz University of Medical Sciences","has_results":false},{"nct_id":"NCT03591874","title":"Study of Brimonidine Tartrate Nanoemulsion Eye Drops in Patients With Ocular Graft-vs-Host Disease","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":59,"lead_sponsor_name":"Ocugen","has_results":true},{"nct_id":"NCT05368181","title":"MAP-guided Preemptive Therapy of aGvHD","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":56,"lead_sponsor_name":"Sichuan University","has_results":false},{"nct_id":"NCT02336230","title":"A Prospective Study of Remestemcel-L, Ex-vivo Cultured Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Participants Who Have Failed to Respond to Steroid Treatment for Acute Graft-Versus-Host Disease (aGVHD)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":55,"lead_sponsor_name":"Mesoblast, Inc.","has_results":true},{"nct_id":"NCT07509749","title":"Novel Therapies for Severe Acute GVHD (Graft-versus-host Disease)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":54,"lead_sponsor_name":"Daihong Liu","has_results":false},{"nct_id":"NCT07246031","title":"BPC2001 for the Prevention of Acute Graft-Versus-Host Disease Following Haploidentical Stem Cell Transplantation","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"BioPhoenix Co., Ltd.","has_results":false},{"nct_id":"NCT04118556","title":"Decidua Stroma Cells for Steroid Resistent Acute Graft-versus-host Disease After Allo-HSCT","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Mats Remberger","has_results":false},{"nct_id":"NCT03631589","title":"MSC for Severe aGVHD","phase":"PHASE2, PHASE3","overall_status":"UNKNOWN","enrollment_count":50,"lead_sponsor_name":"Fujian Medical University","has_results":false},{"nct_id":"NCT07508345","title":"Endothelial Dysfunction as a Predictive Marker of Acute Graft-Versus-Host Disease in Adult Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation","phase":"","overall_status":"COMPLETED","enrollment_count":50,"lead_sponsor_name":"Fondazione IRCCS Policlinico San Matteo di Pavia","has_results":false},{"nct_id":"NCT06663722","title":"Axatilimab in Combination With Extracorporeal Photopheresis (ECP) in Chronic Graft-versus-Host Disease","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":49,"lead_sponsor_name":"University of Miami","has_results":false},{"nct_id":"NCT04014790","title":"RGI-2001 for the Prevention of Acute Graft-vs-Host Disease in Subjects Following Allogeneic Hematopoietic Stem Cell Transplantation","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":49,"lead_sponsor_name":"Regimmune Corporation","has_results":true},{"nct_id":"NCT03616184","title":"Study of Ruxolitinib in Sclerotic Chronic Graft-Versus-Host Disease After Failure of Systemic Glucocorticoids","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":49,"lead_sponsor_name":"University of Nebraska","has_results":true}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}